Blockchain Registration Transaction Record

NanoViricides Advances MPox Treatment with NV-387 Oral Gummies in Phase II Trial

NanoViricides, Inc. is finalizing a Phase II trial for NV-387 oral gummies to treat MPox, potentially marking a first in human efficacy against orthopoxviruses.

The development of NV-387 by NanoViricides represents a potential breakthrough in the treatment of MPox and other orthopoxvirus infections, addressing a critical gap in current antiviral therapies. With existing treatments showing limited efficacy or adverse effects, NV-387's success could offer a safer, more effective option for patients worldwide, particularly in regions like Africa where MPox remains a significant health threat. This advancement not only highlights the importance of innovative antiviral research but also underscores the global need for accessible and effective treatments against emerging and re-emerging infectious diseases.